Literature DB >> 26755433

The Dietary Flavonoid Fisetin Causes Cell Cycle Arrest, Caspase-Dependent Apoptosis, and Enhanced Cytotoxicity of Chemotherapeutic Drugs in Triple-Negative Breast Cancer Cells.

Matthew L Smith1, Kaylee Murphy2, Carolyn D Doucette3, Anna L Greenshields3, David W Hoskin1,2,3.   

Abstract

Fisetin (3,3',4',7-tetrahydroxyflavone), a flavonoid found in a number of fruits and vegetables, has diverse biological activities, including cytotoxic effects on cancer cells. In this study, we investigated the effect of fisetin on triple-negative breast cancer (TNBC) cells. TNBC has a poorer prognosis than other types of breast cancer and treatment options for this disease are limited. Fisetin inhibited the growth of MDA-MB-468 and MDA-MB-231 TNBC cells, as well as their ability to form colonies, without substantially affecting the growth of non-malignant cells. In addition, fisetin inhibited the growth of estrogen receptor-bearing MCF-7 breast cancer cells and human epidermal growth factor receptor 2-overexpressing SK-BR-3 breast cancer cells. Fisetin inhibited TNBC cell division and induced apoptosis, which was associated with mitochondrial membrane permeabilization and the activation of caspase-9 and caspase-8, as well as the cleavage of poly(ADP-ribose) polymerase-1. Induction of caspase-dependent apoptosis by fisetin was confirmed by reduced killing of TNBC cells in the presence of the pan-caspase inhibitors Z-VAD-FMK and BOC-D-FMK. Decreased phosphorylation of histone H3 at serine 10 in fisetin-treated TNBC cells at G2/M phase of the cell cycle suggested that fisetin-induced apoptosis was the result of Aurora B kinase inhibition. Interestingly, the cytotoxic effect of cisplatin, 5-fluorouracil, and 4-hydroxycyclophosphamide metabolite of cyclophosphamide on TNBC cells was increased in the presence of fisetin. These findings suggest that further investigation of fisetin is warranted for possible use in the management of TNBC. J. Cell. Biochem. 117: 1913-1925, 2016.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  APOPTOSIS; BREAST CANCER; CELL CYCLE ARREST; CHEMOTHERAPY; FISETIN; FLAVONOID

Mesh:

Substances:

Year:  2016        PMID: 26755433     DOI: 10.1002/jcb.25490

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  14 in total

1.  Follicle inhibition at the primordial stage without increasing apoptosis, with a combination of everolimus, verapamil.

Authors:  Michail Pargianas; Ioannis Kosmas; Kyriaki Papageorgiou; Chrysoula Kitsou; Alexandra Papoudou-Bai; Anna Batistatou; Sofia Markoula; Styliani Salta; Alexandros Dalkalitsis; Stratis Kolibianakis; Basil C Tarlatzis; Ioannis Georgiou; Theologos M Michaelidis
Journal:  Mol Biol Rep       Date:  2020-10-20       Impact factor: 2.316

Review 2.  Fisetin, a Potent Anticancer Flavonol Exhibiting Cytotoxic Activity against Neoplastic Malignant Cells and Cancerous Conditions: A Scoping, Comprehensive Review.

Authors:  Robert Kubina; Kamil Krzykawski; Agata Kabała-Dzik; Robert D Wojtyczka; Ewa Chodurek; Arkadiusz Dziedzic
Journal:  Nutrients       Date:  2022-06-23       Impact factor: 6.706

3.  The Natural Flavonoid Fisetin Inhibits Cellular Proliferation of Hepatic, Colorectal, and Pancreatic Cancer Cells through Modulation of Multiple Signaling Pathways.

Authors:  Mаhmoud Youns; Wael Abdel Halim Hegazy
Journal:  PLoS One       Date:  2017-01-04       Impact factor: 3.240

4.  The neuroprotective mechanism of 2-arachidonoylglycerol 2-AG against non-caspase-dependent apoptosis in mice hippocampal neurons following MCAO.

Authors:  He-Ying Zhong; Zhou Yang; Zhen Qiu; Shao-Qing Lei; Zhong-Yuan Xia
Journal:  Neuropsychiatr Dis Treat       Date:  2019-08-23       Impact factor: 2.570

5.  Cellular and molecular alterations induced by low‑dose fisetin in human chronic myeloid leukemia cells.

Authors:  Anna Klimaszewska-Wiśniewska; Dariusz Grzanka; Paulina Czajkowska; Marta Hałas-Wiśniewska; Justyna Durślewicz; Paulina Antosik; Alina Grzanka; Maciej Gagat
Journal:  Int J Oncol       Date:  2019-10-02       Impact factor: 5.650

6.  Dimethyl celecoxib sensitizes gastric cancer cells to ABT-737 via AIF nuclear translocation.

Authors:  Bo Zhang; Youyou Yan; Yangling Li; Dan Zhang; Jianmei Zeng; Linling Wang; Mimi Wang; Nengming Lin
Journal:  J Cell Mol Med       Date:  2016-07-04       Impact factor: 5.310

7.  Anti‑cancer effects of fisetin on mammary carcinoma cells via regulation of the PI3K/Akt/mTOR pathway: In vitro and in vivo studies.

Authors:  Xu Sun; Xueman Ma; Qiwei Li; Yong Yang; Xiaolong Xu; Jiaqi Sun; Mingwei Yu; Kexin Cao; Lin Yang; Guowang Yang; Ganlin Zhang; Xiaomin Wang
Journal:  Int J Mol Med       Date:  2018-05-02       Impact factor: 4.101

Review 8.  The "Yin and Yang" of Natural Compounds in Anticancer Therapy of Triple-Negative Breast Cancers.

Authors:  Elizabeth Varghese; Samson Mathews Samuel; Mariam Abotaleb; Sohaila Cheema; Ravinder Mamtani; Dietrich Büsselberg
Journal:  Cancers (Basel)       Date:  2018-09-21       Impact factor: 6.639

9.  Fisetin Inhibited Growth and Metastasis of Triple-Negative Breast Cancer by Reversing Epithelial-to-Mesenchymal Transition via PTEN/Akt/GSK3β Signal Pathway.

Authors:  Jie Li; Xia Gong; Rong Jiang; Dan Lin; Tao Zhou; Aijie Zhang; Hongzhong Li; Xiang Zhang; Jingyuan Wan; Ge Kuang; Hongyuan Li
Journal:  Front Pharmacol       Date:  2018-07-31       Impact factor: 5.810

10.  GSK-3β-Targeting Fisetin Promotes Melanogenesis in B16F10 Melanoma Cells and Zebrafish Larvae through β-Catenin Activation.

Authors:  Ilandarage Menu Neelaka Molagoda; Wisurumuni Arachchilage Hasitha Maduranga Karunarathne; Sang Rul Park; Yung Hyun Choi; Eui Kyun Park; Cheng-Yun Jin; Haiyang Yu; Wol Soon Jo; Kyoung Tae Lee; Gi-Young Kim
Journal:  Int J Mol Sci       Date:  2020-01-02       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.